HomeCompareCPBLF vs PFE

CPBLF vs PFE: Dividend Comparison 2026

CPBLF yields 1.86% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CPBLF wins by $130.5K in total portfolio value
10 years
CPBLF
CPBLF
● Live price
1.86%
Share price
$14.00
Annual div
$0.26
5Y div CAGR
57.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$180.0K
Annual income
$85,187.51
Full CPBLF calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CPBLF vs PFE

📍 CPBLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCPBLFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CPBLF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CPBLF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CPBLF
Annual income on $10K today (after 15% tax)
$157.86/yr
After 10yr DRIP, annual income (after tax)
$72,409.38/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, CPBLF beats the other by $50,089.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CPBLF + PFE for your $10,000?

CPBLF: 50%PFE: 50%
100% PFE50/50100% CPBLF
Portfolio after 10yr
$114.8K
Annual income
$55,723.12/yr
Blended yield
48.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CPBLF
No analyst data
Price Target
$28.00
+100.0% upside vs current
Range: $28.00 — $28.00
Altman Z
4.9
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CPBLF buys
0
PFE buys
0
No recent congressional trades found for CPBLF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCPBLFPFE
Forward yield1.86%6.13%
Annual dividend / share$0.26$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR57.7%13.2%
Portfolio after 10y$180.0K$49.6K
Annual income after 10y$85,187.51$26,258.71
Total dividends collected$150.3K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst price target$28.00$27.50

Year-by-year: CPBLF vs PFE ($10,000, DRIP)

YearCPBLF PortfolioCPBLF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$10,993$292.87$9,153$693.39+$1.8KCPBLF
2$12,237$474.50$8,593$849.25+$3.6KCPBLF
3$13,872$778.47$8,336$1,066.78+$5.5KCPBLF
4$16,144$1,300.64$8,437$1,384.80+$7.7KCPBLF
5$19,504$2,230.84$9,013$1,875.40+$10.5KCPBLF
6$24,842$3,972.39$10,306$2,680.72+$14.5KCPBLF
7$34,038$7,456.83$12,820$4,101.38+$21.2KCPBLF
8$51,479$15,058.31$17,673$6,826.70+$33.8KCPBLF
9$88,648$33,565.26$27,543$12,591.86+$61.1KCPBLF
10$180,041$85,187.51$49,560$26,258.71+$130.5KCPBLF

CPBLF vs PFE: Complete Analysis 2026

CPBLFStock

ALS Limited provides professional technical services primarily in the areas of testing, measurement, and inspection in Africa, Asia/Pacific, Europe, the Middle East, North Africa, and the Americas. The company operates through three segments: Life Sciences, Commodities, and Industrial. The Commodities segment offers assaying and analytical testing, and metallurgical services for the mining and mineral exploration companies in geochemistry, metallurgy, inspection, and coal quality streams. Its testing and consulting services cover the resource life cycle, including exploration, feasibility, optimization, production, design, development, trade, and rehabilitation. This segment also provides coal sampling, analysis and certification, formation evaluation, and related analytical testing services. The Life Sciences segment offers analytical testing and sampling, and remote monitoring services for the environmental, food, pharmaceutical, and consumer products markets; and microbiological, physical, and chemical testing services. This segment also provides analytical testing data to assist consulting and engineering firms, industries, and governments. The Industrial segment offers diagnostic testing and engineering solutions for the energy, resources, transportation, and infrastructure sectors. This segment serves asset owners, operators, constructors, and equipment manufacturers in the power, petrochemical, mining, minerals processing, water, infrastructure, and transportation industries. The company was formerly known as Campbell Brothers Limited and changed its name to ALS Limited in August 2012. ALS Limited was founded in 1863 and is headquartered in Milton, Australia.

Full CPBLF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CPBLF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CPBLF vs SCHDCPBLF vs JEPICPBLF vs OCPBLF vs KOCPBLF vs MAINCPBLF vs JNJCPBLF vs MRKCPBLF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.